CD27/TNFRSF7 Antibody (012)

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-90423

Recombinant Monoclonal Antibody
Novus Biologicals, part of Bio-Techne

Key Product Details

Species Reactivity

Mouse

Applications

Flow Cytometry, Immunocytochemistry/ Immunofluorescence

Label

Unconjugated

Antibody Source

Recombinant Monoclonal Rabbit IgG Clone # 012

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

View all CD27/TNFRSF7 Antibodies »

Product Specifications

Immunogen

This antibody was obtained from a rabbit immunized with purified, recombinant Mouse CD27/TNFRSF7 (Accession#: NP_001028298.1; Met1-Arg182).

Clonality

Monoclonal

Host

Rabbit

Isotype

IgG

Description

This antibody can be stored at 2C-8C for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20C to -80C. Avoid repeated freeze-thaw cycles.

Scientific Data Images for CD27/TNFRSF7 Antibody (012)

Immunocytochemistry/ Immunofluorescence: CD27/TNFRSF7 Antibody (012) [NBP2-90423]

Immunocytochemistry/ Immunofluorescence: CD27/TNFRSF7 Antibody (012) [NBP2-90423]

Immunocytochemistry/Immunofluorescence: CD27/TNFRSF7 Antibody (012) [NBP2-90423] - Immunofluorescence staining of Mouse CD27/TNFRSF7 in Mouse Spleen cells. Cells were fixed with 4% PFA, blocked with 10% serum, and incubated with rabbit anti-mouse CD27/TNFRSF7 monoclonal antibody (1:60) at 37C 1 hour. Then cells were stained with the Alexa Fluor(R) 488-conjugated Goat Anti-rabbit IgG secondary antibody (green). Positive staining was localized to cell membrane.
Flow Cytometry: CD27/TNFRSF7 Antibody (012) [NBP2-90423]

Flow Cytometry: CD27/TNFRSF7 Antibody (012) [NBP2-90423]

Flow Cytometry: CD27/TNFRSF7 Antibody (012) [NBP2-90423] - Flow cytometric analysis of Mouse IFN-alpha/beta R1 expression on BABL/c splenocytes. Cells were stained with Mouse BD Fc Block(TM) purified anti-mouse CD16/CD32 mAb, then stained with purified anti-Mouse IFN-alpha/beta R1, then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
Flow Cytometry: CD27/TNFRSF7 Antibody (012) [NBP2-90423]

Flow Cytometry: CD27/TNFRSF7 Antibody (012) [NBP2-90423]

Flow Cytometry: CD27/TNFRSF7 Antibody (012) [NBP2-90423] - Expression of CD27/TNFRSF7 on mouse splenocytes. BABL/c splenocytes were stained with purified mAb R012, then a FITC-conjugated second step antibody . Flow cytometry was performed on a BD FACSCalibur(TM) flow cytometry system.

Applications for CD27/TNFRSF7 Antibody (012)

Application
Recommended Usage

Flow Cytometry

1:25-1:100

Immunocytochemistry/ Immunofluorescence

1:20-1:100

Formulation, Preparation, and Storage

Purification

Protein A purified

Formulation

0.2 um filtered solution in PBS

Preservative

No Preservative

Concentration

Please see the vial label for concentration. If unlisted please contact technical services.

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: CD27/TNFRSF7

CD27, also referred to as tumor necrosis factor receptor superfamily, member 7 (TNFRSF7), is a type I transmembrane glycoprotein that functions as a co-stimulatory T cell receptor and is expressed on the surface of T cells, natural killer (NK) cells, and B cells (1,2). The human CD27 protein is 260 amino acids (aa) in length and consists of a 19 aa signal sequence, 172 aa extracellular domain (ECD) containing three characteristic cysteine-rich domains (CRDs), a 21 aa helical transmembrane region, and a 48 aa cytoplasmic tail domain (3,4). The CD27 protein has a theoretical molecular weight (MW) of 29 kDa, but is typically is closer to 50-55 kDa due to N-linked and O-linked glycosylation (3). Mouse CD27 cDNA encodes a 250 aa protein with a theoretical molecular weight of 28 kDa (5). Human CD27 shares ~64% aa sequence identity with mouse CD27 protein.

Membrane-bound CD27 is expressed as a disulfide-linked homodimer (3). CD27 binds to the ligand CD70, a transmembrane glycoprotein that is transiently expressed on activated immune cells such as antigen presenting cells (APCs), dendritic cells (DCs), NK cells, B cells, and T cells (1,2,6,7). The receptor-ligand binding interaction leads to NFkappaB and c-Jun pathway activation which promotes immune stimulation and activation and survival of CD4+ T cells, CD8+ T cells, memory T cells, and NK cells (2,6,7). Both CD27 and CD70 are often abnormally expressed or dysregulated on malignant and cancer cells leading to immune evasion and tumor progression (7). CD27 has become a target of interest of immunotherapies for viral infections, autoimmune disease, and cancer (2). Varlilumab, an agonistic CD27 monoclonal antibody (mAB), has entered clinical trials for the treatment of hematological and solid tumor cancers (1,6). Additional clinical trials are in process that combine varlilumab with other immune checkpoint inhibitors like the programmed cell death protein-1 (PD-1) blocking mAb nivolumab (1,2). Initial results are promising, suggesting that targeting CD27, especially in combination with other therapeutics, may be a promising and effective immunotherapy for a variety of pathologies (1,2,6).

References

1. Starzer AM, Berghoff AS. New emerging targets in cancer immunotherapy: CD27 (TNFRSF7). ESMO Open. 2020;4(Suppl 3):e000629. https://doi.org/10.1136/esmoopen-2019-000629

2. Grant EJ, Nussing S, Sant S, Clemens EB, Kedzierska K. The role of CD27 in anti-viral T-cell immunity. Curr Opin Virol. 2017;22:77-88. https://doi.org/10.1016/j.coviro.2016.12.001

3. Buchan SL, Rogel A, Al-Shamkhani A. The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy. Blood. 2018;131(1):39-48. https://10.1182/blood-2017-07-741025

4. Uniprot (P26842)

5. Uniprot (P41272)

6. van de Ven K, Borst J. Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. Immunotherapy. 2015;7(6):655-667. https://doi.org/10.2217/imt.15.32

7. Flieswasser T, Van den Eynde A, Van Audenaerde J, et al. The CD70-CD27 axis in oncology: the new kids on the block. J Exp Clin Cancer Res. 2022;41(1):12. https://doi.org/10.1186/s13046-021-02215-y

Alternate Names

CD27, TNFRSF7

Gene Symbol

CD27

Additional CD27/TNFRSF7 Products

Product Documents for CD27/TNFRSF7 Antibody (012)

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Download SDS

Product Specific Notices for CD27/TNFRSF7 Antibody (012)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.